Insider Selling: Genomic Health Inc. (GHDX) COO Sells 8,290 Shares of Stock
Genomic Health Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 8,290 shares of Genomic Health stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $30.59, for a total value of $253,591.10. Following the transaction, the chief operating officer now directly owns 39,426 shares in the company, valued at approximately $1,206,041.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
G Bradley Cole also recently made the following trade(s):
- On Thursday, August 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $28.87, for a total value of $144,350.00.
Shares of Genomic Health Inc. (NASDAQ:GHDX) traded down 5.15% during mid-day trading on Wednesday, hitting $28.91. The company’s stock had a trading volume of 215,779 shares. Genomic Health Inc. has a 52-week low of $20.05 and a 52-week high of $35.79. The stock’s 50 day moving average price is $28.21 and its 200 day moving average price is $27.28. The company’s market cap is $964.03 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/insider-selling-genomic-health-inc-ghdx-coo-sells-8290-shares-of-stock.html
Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.18). Genomic Health had a negative return on equity of 21.02% and a negative net margin of 8.84%. The firm earned $81.97 million during the quarter, compared to analyst estimates of $81.27 million. During the same quarter in the prior year, the company earned ($0.29) EPS. The business’s revenue was up 16.1% compared to the same quarter last year. Equities analysts forecast that Genomic Health Inc. will post ($0.47) EPS for the current year.
Several research analysts recently issued reports on the company. Zacks Investment Research cut Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Leerink Swann reaffirmed a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st. Jefferies Group lifted their target price on Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, August 17th. Bank of America Corp. set a $28.00 target price on Genomic Health and gave the company a “sell” rating in a research report on Wednesday, August 3rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $38.00 target price on shares of Genomic Health in a research report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $32.50.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Loomis Sayles & Co. L P purchased a new position in shares of Genomic Health during the first quarter valued at about $15,639,000. Eagle Asset Management Inc. bought a new position in shares of Genomic Health during the third quarter worth about $8,417,000. Ghost Tree Capital LLC bought a new position in shares of Genomic Health during the second quarter worth about $5,179,000. Renaissance Technologies LLC boosted its position in shares of Genomic Health by 54.0% in the first quarter. Renaissance Technologies LLC now owns 446,021 shares of the company’s stock worth $11,048,000 after buying an additional 156,421 shares during the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in shares of Genomic Health during the second quarter worth about $1,983,000. 88.92% of the stock is owned by hedge funds and other institutional investors.
About Genomic Health
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.